Method for safe and sustainable recycling of waste The method developed by RIVM to assess whether waste treatment is sufficiently safe and sustainable, can contribute to the European ambitions for a safe and more circular economy.
RIVM international circular economy knowledge partner As of 7 December 2020, RIVM has become a knowledge partner of the international Platform for Accelerating the Circular Economy (PACE).
Population screening programmes temporarily on hold Due to the novel coronavirus (COVID-19) outbreak, the health care capacity in the Netherlands is expected to come under severe pressure in the coming period.
Control measures against the spread of Legionella from wastewater treatment plants Wastewater treatment plants (WWTPs) may spread Legionella via the air and cause pneumonia if people inhale them.
A guide for the safe reuse of diaper and incontinence materials RIVM has developed a step-by-step plan for the safe reuse of diapers and incontinence material. This plan provides recyclers and licensing authorities with tools to carry out a risk assessment.
Call for circular designers If you work on a circular solution or products, you can get lost in the complexity of quality labels, marketing strategies, advice and prohibitions.
Emphasising safety and sustainability in circular design A stronger focus on safety, health and sustainability is needed in designing circular products. When basic resources are re-used in new products, health risks should be avoided.
CleaR delivers framework for risk assessment of substances of concern in the recycling process For a successful circular economy, it is essential to improve the conditions in which materials and products are recycled once they have reached the end of their life cycle.
Biosafety and Biosecurity on the Global Health Security Agenda Since 2018, the Netherlands leads the way in the field of "Biosafety and Biosecurity" within the international Global Health Security Agenda (GHSA).
Global Infectious Disease Control hampered by the CBD Nagoya Protocol So far, none of the models used by international networks of biobanks to arrange the legal responsibility under the CBD-Nagoya protocol works efficiently.